DXCM|Analyst Targets
DXCM|Company Info
DXCM|Insider Trading
DXCM|Fundamentals
DXCM|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.67 | - | - |
| Q2'26 | $0.61 | $0.70 | +15.1% |
| Q1'26 | $0.47 | $0.56 | +19.0% |
| Q4'25 | $0.48 | $0.68 | +42.8% |
| Q3'25 | $0.57 | $0.61 | +7.5% |
| Q2'25 | $0.44 | $0.48 | +8.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.4B | - | - |
| Q2'26 | $1.3B | $1.3B | +1.4% |
| Q1'26 | $1.2B | $1.2B | +1.5% |
| Q4'25 | $1.2B | $1.3B | +6.5% |
| Q3'25 | - | $1.2B | - |
| Q2'25 | - | $1.2B | - |
DXCM|Monthly Returns
Market Data
DXCM Stock Snapshot
- Market cap
- 32.36B
- P/E ratio
- 32.4
- Day range
- $84.77 – $86.18
- News sentiment
- 66/100 · Bullish
- Analyst target
- $96.23 (+13.1%)
- Consensus
- Buy · 38 analysts
Momentum is working in DXCM's favour - it ranks in the upper part of DailyIQ's momentum universe. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Behaviour On Record
What DXCM's own history says about today's numbers
- Realized volatility (21d)
- 25.0% 9th pct
- Below its peak
- -47.8%
- vs 200-day average
- +15.6%
- Up days (1y)
- 53%
DexCom, Inc. is currently running 25.0% annualised volatility over the last 21 sessions. Measured against DXCM's own 13 years of daily returns rather than a market-wide average, that is the 9th percentile — unusually subdued by its own history, against a typical reading of 37.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
DXCM is trading -47.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -38.9%, and the deepest was -54.4% in 2024. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +15.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 65th percentile — a somewhat wider gap than its own norm. Over the past year DXCM closed higher on 53% of sessions, and it is currently 1 session into a falling streak.
On October specifically: over 13 years of records, DXCM finished the month higher 5 of 13 times, with a median return of -2.6% and an average of +1.3%. Its strongest month historically has been November at +10.1% on average, its weakest September at -7.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: DXCM has opened more than 2% away from the prior close in 134 of 3,266 sessions (4.1% of the time), with the largest gaps running +8.1% and -15.3%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, DXCM moved an average of 5.6% in the session after earnings, closing higher 3 of those 3 times, with a median move of +6.0% and a largest of +8.3%.
All figures computed from 3,267 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against DXCM's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of DXCM's sector?
DexCom, Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, DXCM ranks 3rd of 15 tracked industries, improving.
- Sector rank
- #3 of 12
- Sector state
- Leading
- Sector rotation score
- 91
- Industry rank
- #3 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on DXCM?
BTIG most recently reiterated its rating on DexCom, Inc. to Buy on Oct 12, 2026 with a price target of $96 (from $90). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- BTIG — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
DXCM peers & ETF holders
Medical DevicesMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▼ Sell | 49,074,378 | 12.92% | $3.26B | 2026-01-29 |
| BlackRock, Inc. | ▼ Sell | 38,244,137 | 10.07% | $2.58B | 2026-08-07 |
| Invesco Ltd. | ▲ Buy | 15,288,133 | 4.03% | $1.03B | 2026-08-14 |
| Baillie Gifford & Co | ▼ Sell | 14,801,590 | 3.90% | $996.89M | 2026-08-06 |
| Geode Capital Management, LLC | ▲ Buy | 12,426,515 | 3.27% | $834.17M | 2026-08-12 |
| AllianceBernstein L.P. | ▼ Sell | 11,693,409 | 3.08% | $734.35M | 2026-08-14 |
| Wellington Management Group LLP | ▼ Sell | 8,527,471 | 2.25% | $574.33M | 2026-08-14 |
| Norges Bank | ▼ Sell | 6,868,090 | 1.81% | $462.57M | 2026-08-12 |
| Morgan Stanley | ▲ Buy | 5,156,282 | 1.36% | $347.28M | 2026-08-13 |
| Goldman Sachs Group Inc | ▲ Buy | 3,758,616 | 0.99% | $253.14M | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 3,325,095 | 0.88% | $232.69M | 2026-08-12 |
| Northern Trust Corp | ▼ Sell | 3,295,144 | 0.87% | $221.93M | 2026-08-13 |
| AQR Capital Management LLC | ▲ Buy | 3,237,720 | 0.85% | $218.06M | 2026-08-14 |
| Bank of America Corp | ▲ Buy | 3,163,604 | 0.83% | $213.07M | 2026-08-14 |
| Janus Henderson Group plc | ▲ Buy | 2,644,539 | 0.70% | $166.08M | 2026-05-18 |
| FMR LLC (Fidelity) | ▲ Buy | 1,893,246 | 0.50% | $127.51M | 2026-08-13 |
| Renaissance Technologies LLC | ▲ Buy | 1,630,796 | 0.43% | $109.83M | 2026-08-13 |
| Citadel Advisors LLC | ▼ Sell | 1,211,767 | 0.32% | $81.61M | 2026-09-02 |
| Susquehanna International Group, LLP | ▲ Buy | 1,043,864 | 0.27% | $70.30M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 1,011,869 | 0.27% | $68.15M | 2026-08-14 |
| Adage Capital Partners GP, L.L.C. | ▼ Sell | 999,900 | 0.26% | $67.34M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 956,398 | 0.25% | $64.41M | 2026-08-03 |
| Neuberger Berman Group LLC | ▼ Sell | 736,024 | 0.19% | $49.57M | 2026-08-13 |
| Marshall Wace, LLP | ▲ Buy | 532,804 | 0.14% | $35.88M | 2026-08-13 |
| Bridgewater Associates, LP | ▲ Buy | 400,929 | 0.11% | $27.00M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Tina Smith | Senate | MN | ▼ Sell | $100K - $250K | 2026-05-07 | 2026-05-10 |
| Tina Smith | Senate | MN | ▼ Sell | $100K - $250K | 2026-04-29 | 2026-05-10 |
| John Boozman | Senate | AR | ▲ Buy | $1K - $15K | 2026-01-26 | 2026-02-15 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-05-15 | 2025-06-09 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-05-08 | 2025-06-22 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-04-08 | 2025-04-28 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-04-07 | 2025-05-08 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-02-25 | 2025-03-27 |
| Kevin Hern | House | OK01 | ▼ Sell | $50K - $100K | 2024-12-31 | 2025-01-15 |
| Tina Smith | Senate | MN | ▼ Sell | $250K - $500K | 2020-03-17 | 2020-04-16 |